


Participant Flow



Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; LRYGB, laparoscopic Roux-en-Y gastric bypass; LSG, laparoscopic sleeve gastrectomy.

Baseline Characteristics

Table 1. Descriptive characteristics of the participants at baseline

| Parameters | Group <i>n</i> =84 | VLCD <i>n</i> =43 | LCD <i>n</i> =41 |
|--------------------------------------|-----------------------|----------------------|---------------------|
| Gender, female (<i>n</i> /%) | 63 (75%) | 29 (67.5%) | 34 (82.9%) |
| Age (years) | 45.3±10.1 | 45.2±10.5 | 45.5±9.7 |
| Weight (kg) | 129.1±20.2 | 131.9±22.6 | 126.2±17.1 |
| Height (cm) | 165.1±8.4 | 166.7±9.4 | 163.4±6.8 |
| Body mass index (kg/m ²) | 47.3±5.2 | 47.3±5.3 | 47.2±5.0 |
| Waist (cm) | 135.8±15.1 | 137.3±16.5 | 134.2±13.5 |
| SBP (mmHg) | 147.8±24.3 | 145.8±30.0 | 149.7±17.6 |
| DBP (mmHg) | 91.8±12.5 | 91.4±13.2 | 92.2±12.1 |
| Comorbidities | | | |
| Type 2 diabetes (<i>n</i> /%) | 15 (17.9%) | 11 (25.6%) | 4 (9.8%) |
| Dyslipidemia (<i>n</i> /%) | 35 (41.7%) | 20 (46.5%) | 15 (36.6%) |
| Hypertension (<i>n</i> /%) | 41 (48.8%) | 24 (55.8%) | 17 (41.5%) |
| OSAS (<i>n</i> /%) | 19 (22.6%) | 11 (25.6%) | 8 (19.5%) |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; OSAS, obstructive sleep apnea syndrome; Results are expressed as mean ± standard deviation or number and percentage of individuals.

Outcome Measures

Primary outcome measures

Table 2. Changes in hepatic volume before and after a VLCD or LCD.

| Parameters | | Baseline (cc) | Final | Change (cc) | Change (%) | Intra groups | |
|--|-------------------------------|------------------|--------------|----------------|---------------|--------------|----------------------------------|
| Total participants | | | | | | P-value | Adjusted P-value [†] |
| | VLCD (N=34) | 2653±654 | 2208±458 | -445±432 | -15,6±11,2 | <0.001 | 0.045 |
| | LCD (N=38) | 2600±833 | 2268±775 | -332±340 | -12,3±10,6 | <0.001 | 0.045 |
| | P-value* | 0.768 | 0.873 | 0.222 | 0.212 | | |
| | Adjusted P-value [†] | 0.923 | 0.923 | 0.409 | 0.409 | | |
| Participants with a hepatic volume < 3L | | | | | | | |
| | VLCD (N=25) | 2355±320 | 2010±303 | -345±226 | -14.4±9.1 | <0.001 | 0.045 |
| | LCD (N=32) | 2342±401 | 2071±360 | -271±222 | -11.3±8.5 | <0.001 | 0.045 |
| | P-value | 0.898 | 0.503 | 0.227 | 0.190 | | |
| | Adjusted P-value | 0.923 | 0.696 | 0.409 | 0.409 | | |
| Participants with a hepatic volume > 3 L | | | | | | | |
| | VLCD (N=9) | 3480±643 | 2757.2±360.3 | -723±707 | -18.8±15.9 | 0.015 | 0.054 |
| | LCD (N=6) | 3975±1203 | 3317±1439 | -657±632 | -18.0±18.3 | 0.052 | 0.156 |
| | P-value | 0.316 | 0.390 | 0.857 | 0.923 | | |
| | Adjusted P-value | 0.0517 | 0.585 | 0.923 | 0.923 | | |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; cc: cubic centimeters; NS, not significant.

Results are expressed as mean ± standard deviation. To determine differences between groups a U was applied.

*: P value for between-group differences.

†The Benjamin-Hockberg procedure for multiple-testing was used to calculate adjusted P-values, considering an FDR <0.05 as significant.

Secondary outcomes

Table 3. Changes in weight, body composition and blood pressure after 21 days of VLCD or LCD interventions.

| Parameters | Diet | Baseline | Final | Change | Intra groups | |
|--------------------------|--|--|--|--|------------------|-------------------------------|
| | | | | | P-value | Adjusted P-value [†] |
| Weight (kg) | VLCD (n=42) LCD (n=41) P-value* Adjusted P-value [†] | 131.2±22.4 126.2±17.1 0.257 0.402 | 123.6±21.0 120.8±16.0 0.511 0.608 | -7.65±2.66 -5.36±2.21 <0.001 0.002 | <0.001 <0.001 | 0.002 0.002 |
| TWL (%) | VLCD (n=42) LCD (n=41) P-value* Adjusted P-value [†] | 131.2±22.4 126.2±17.1 0.257 0.402 | 123.6±21.0 120.8±16.0 0.511 0.608 | -5.81±1.71 -4.19±1.55 <0.001 0.002 | <0.001 <0.001 | 0.002 0.002 |
| BMI (kg/m ²) | VLCD (n=42) LCD (n=41) P-value* Adjusted P-value [†] | 47.2±5.4 47.2±5.0 0.984 0.984 | 44.5±5.6 45.2±4.8 0.504 0.068 | -2.73±0.82 -2.01±0.81 <0.001 0.002 | <0.001 <0.001 | 0.002 0.002 |
| Waist circumference (cm) | VLCD (n=42) LCD (n=41) P-value* Adjusted P-value [†] | 137.2±16.7 134.2±13.5 0.388 0.530 | 131.2±15.3 129.5±11.0 0.576 0.670 | -5.95±7.13 -4.77±7.01 0.453 0.581 | <0.001 <0.001 | 0.002 0.002 |
| Fat (kg) | VLCD (n=42) LCD (n=40) P-value* Adjusted P-value [†] | 66.2±16.6 63.7±14.4 0.605 0.681 | 62.0±15.6 61.1±11.0 0.752 0.800 | -4.11±4.43 -2.67±3.14 0.094 0.188 | <0.001 <0.001 | 0.002 0.002 |
| Lean mass (Kg) | VLCD (n=42) LCD (n=40) P-value* Adjusted P-value [†] | 65.0±15.2 61.6±7.1 0.207 0.379 | 61.5±13.0 58.9±6.9 0.247 0.402 | -3.52±4.59 -2.78±3.32 0.408 0.537 | <0.001 <0.001 | 0.002 0.002 |
| Muscle mass (Kg) | VLCD (n=42) LCD (n=40) P-value* Adjusted P-value [†] | 61.8±14.5 58.5±6.8 0.202 0.379 | 58.4±12.4 55.9±6.5 0.247 0.402 | -3.38±4.44 -2.65±3.17 0.392 0.530 | <0.001 <0.001 | 0.002 0.002 |
| Water (Kg) | VLCD (n=33) LCD (n=36) P-value* Adjusted P-value [†] | 48.3±11.4 45.5±6.1 0.212 0.380 | 45.3±9.9 43.4±5.8 0.360 0.514 | -3.08±1.90 -2.08±2.21 0.050 0.104 | <0.001 <0.001 | 0.002 0.002 |
| SBP (mmHg) | VLCD (n=38) LCD (n=40) P-value* Adjusted P-value [†] | 149.1±21.9 149.7±17.8 0.902 0.940 | 139.4±14.4 141.5±17.0 0.286 0.433 | -9.71±21.85 -8.23±17.05 0.738 0.800 | 0.009 <0.001 | 0.020 0.002 |

| | | | | | | |
|------------|-------------------------------|-----------|------------|-------------|--------|-------|
| DBP (mmHg) | VLCD (<i>n</i> =38) | 91.2±13.3 | 84.7±10.4 | -6.50±13.00 | 0.004 | 0.010 |
| | LCD (<i>n</i> =40) | 92.4±12.1 | 86.06±11.5 | -6.36±10.83 | <0.001 | 0.002 |
| | P-value* | 0.731 | 0.342 | 0.960 | | |
| | Adjusted P-value [†] | 0.800 | 0.503 | 0.980 | | |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; BMI, body mass index; TWL, total weight loss; SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not significant.

Results are expressed as mean ± standard deviation. To determine differences between groups a t-student test was applied.

*: P value for between-group differences.

[†]The Benjamin-Hockberg procedure for multiple-testing was used to calculate adjusted P-values, considering an FDR <0.05 as significant.

Table 4. Changes in glycemic and lipid profiles after 21 days of VLCD or LCD interventions.

| Parameters | Diet | Baseline | Final | Change | Intra groups | |
|-------------------------------------|-------------------------------|---------------|------------------|--------------------|--------------|-------------------------------|
| Glucose profile | | | | | P-value | Adjusted P-value [†] |
| Serum glucose (mg/dL) | VLCD (n=43) | 122.6±49.8 | 97.3±15.4 | -25.3±45.3 | 0.001 | 0.001 |
| | LCD (n=40) | 102.7±33.5 | 95.7±19.2 | -7.0±19.9 | 0.032 | 0.068 |
| | P-value* | 0.032 | 0.670 | 0.021 | | |
| | Adjusted P-value [†] | 0.068 | 0.699 | 0.052 | | |
| HbA_{1c} (%) | VLCD (n=43) | 6.5±1.7 | 6.01±1.2 | -0.5±0.6 | <0.001 | <0.001 |
| | LCD (n=39) | 5.9±1.4 | 5.7±1.2 | -0.2±0.3 | <0.001 | <0.001 |
| | P-value* | 0.597 | 0.270 | 0.037 | | |
| | Adjusted P-value [†] | 0.655 | 0.374 | 0.072 | | |
| Serum insulin (mcUI/mL) | VLCD (n=43) | 23.2±14.1 | 15.0±8.4 | -8.2±10.5 | <0.001 | <0.001 |
| | LCD (n=40) | 19.0±10.5 | 15.0±9.0 | -4.0±6.5 | <0.001 | <0.001 |
| | P-value* | 0.123 | 0.922 | 0.033 | | |
| | Adjusted P-value [†] | 0.213 | 0.922 | 0.068 | | |
| HOMA-IR | VLCD (n=43) | 5.4 (3.4-8.6) | 3.25 (2.1-4.3) | -2.4(-0.9-(-3.4)) | <0.001 | <0.001 |
| | LCD (n=40) | 4.5 (2.9-6.7) | 3.0 (1.9-4.4) | -1.3(+0.01-(-2.2)) | <0.001 | <0.001 |
| | P-value* | 0.074 | 0.424 | 0.019 | | |
| | Adjusted P-value [†] | 0.133 | 0.545 | 0.050 | | |
| Lipid profile | | | | | | |
| Total Cholesterol (mg/dL) | VLCD (n=43) | 182.0±30.8 | 158.3±30.6 | -23.7±23.8 | <0.001 | <0.001 |
| | LCD (n=40) | 190.9±34.9 | 172.7±33.0 | -18.3±21.1 | <0.001 | <0.001 |
| | P-value* | 0.233 | 0.043 | 0.274 | | |
| | Adjusted P-value [†] | 0.338 | 0.081 | 0.374 | | |
| HDL-cholesterol (mg/dL) | VLCD (n=43) | 47.1±10.1 | 39.4±9.5 | -7.7±6.7 | <0.001 | <0.001 |
| | LCD (n=40) | 53.0±12.1 | 46.3±9.9 | -6.8±7.6 | <0.001 | <0.001 |
| | P-value* | 0.013 | 0.002 | 0.547 | | |
| | Adjusted P-value [†] | 0.037 | 0.001 | 0.630 | | |
| LDL-cholesterol (mg/dL) | VLCD (n=43) | 106.6±26.3 | 95.2±30.8 | -11.4±17.33 | <0.001 | <0.001 |
| | LCD (n=40) | 110.9±31.6 | 104.6±29.5 | -6.6±17.1 | 0.022 | 0.052 |
| | P-value* | 0.560 | 0.162 | 0.198 | | |
| | Adjusted P-value [†] | 0.630 | 0.270 | 0.297 | | |
| Triglycerides (mg/dL) | VLCD (n=43) | 126 (97-184) | 107.0 (86-132) | -21(+6-(-55)) | 0.001 | 0.001 |
| | LCD (n=41) | 119 (91-172) | 103 (79.5-132.5) | -13(+7.5-(-50.5)) | 0.002 | 0.006 |
| | P-value* | 0.450 | 0.458 | 0.668 | | |
| | Adjusted P-value [†] | 0.557 | 0.557 | 0.699 | | |
| Uric acid (mg/dL) | VLCD (n=43) | 5.90±1.48 | 6.0±1.7 | +0.06±1.23 | 0.179 | 0.288 |
| | LCD (n=40) | 5.49±1.22 | 6.9±8.9 | +1.39±8.79 | 0.683 | 0.699 |
| | P-value* | 0.193 | 0.508 | 0.328 | | |
| | Adjusted P-value [†] | 0.297 | 0.602 | 0.434 | | |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; HbA1c, glycosylated hemoglobin; HDL, High-density lipoprotein; LDL, low density lipoproteins.

Parameters following a normal distribution are expressed as mean \pm standard deviation and median (interquartile range: 25-75). To determine differences between groups a t-student test was applied as well as a Mann Whitney test. The Wilcoxon test was used for nonparametric paired data.

*: P value for between-group differences.

† The Benjamin-Hockberg procedure for multiple-testing was used to calculate adjusted P-values, considering an FDR <0.05 as significant.

Table 5. Changes in biochemical parameters after 21 days of VLCD or LCD interventions.

| Parameters | Diet | Baseline | Final | Change | Intra groups | |
|------------------------------------|-------------------------------|------------|------------|------------|--------------|-------------------------------|
| Renal function | | | | | P-value | Adjusted P-value [†] |
| Urea (mg/dL) | VLCD (n=43) | 33.4±8.8 | 31.3±12.0 | -2.1±9.9 | 0.749 | 0.832 |
| | LCD (n=39) | 35.64±7.3 | 36.05 | +0.4±6.2 | 0.323 | 0.439 |
| | P-value* | 0.301 | 0.038 | 0.185 | | |
| | Adjusted P-value [†] | 0.426 | 0.100 | 0.308 | | |
| Creatinine (mg/dL) | VLCD (n=43) | 0.71±0.19 | 0.76±0.19 | +0.05±0.11 | 0.005 | 0.022 |
| | LCD (n=40) | 0.74±0.11 | 0.77±0.12 | +0.02±0.06 | 0.020 | 0.067 |
| | P-value* | 0.440 | 0.905 | 0.218 | | |
| | Adjusted P-value [†] | 0.522 | 0.933 | 0.347 | | |
| eGFR (ml/min/1.7) | VLCD (n=43) | 106.6±18.1 | 101.4±19.6 | -5.2±10.0 | <0.001 | 0.001 |
| | LCD (n=40) | 100.1±13.5 | 97.8±14.7 | -2.0±6.8 | <0.001 | 0.001 |
| | P-value* | 0.067 | 0.354 | 0.095 | | |
| | Adjusted P-value [†] | 0.147 | 0.441 | 0.200 | | |
| Hepatic function and liver enzymes | | | | | | |
| AST (UI/L) | VLCD (n=43) | 22.2±12.4 | 29.1±11.2 | +7.0±9.0 | <0.001 | 0.001 |
| | LCD (n=40) | 19.8±5.7 | 22.7±7.7 | +2.9±7.4 | 0.017 | 0.062 |
| | P-value* | 0.251 | 0.003 | 0.028 | | |
| | Adjusted P-value [†] | 0.390 | 0.016 | 0.078 | | |
| ALT (UI/L) | VLCD (n=43) | 27.5±22.6 | 39.8±26.4 | +12.3±19.8 | <0.001 | 0.001 |
| | LCD (n=40) | 24.4±11.1 | 28.7±15.5 | +4.2±12.8 | 0.043 | 0.108 |
| | P-value* | 0.396 | 0.023 | 0.032 | | |
| | Adjusted P-value [†] | 0.478 | 0.070 | 0.086 | | |
| GGT (UI/L) | VLCD (n=43) | 40.2±49.7 | 28.4±26.5 | -11.7±33.5 | 0.027 | 0.078 |
| | LCD (n=40) | 28.5±18.7 | 23.8±16.4 | -4.7±9.8 | 0.004 | 0.02 |
| | P-value* | 0.153 | 0.339 | 0.206 | | |
| | Adjusted P-value [†] | 0.275 | 0.439 | 0.335 | | |
| Leukocyte count | | | | | | |
| Leukocytes (x10 ³ /ul) | VLCD (n=43) | 7.84±2.05 | 6.2±1.5 | -1.60±1.27 | <0.001 | 0.001 |
| | LCD (n=39) | 7.47±1.89 | 6.60±1.6 | -0.87±1.51 | 0.001 | 0.001 |
| | P-value* | 0.349 | 0.296 | 0.020 | | |
| | Adjusted P-value [†] | 0.441 | 0.426 | 0.067 | | |
| Neutrophils (x10 ³ /ul) | VLCD (n=43) | 4.72±1.50 | 3.6±1.1 | -1.14±0.92 | <0.001 | 0.001 |
| | LCD (n=39) | 4.74±1.60 | 4.09±1.27 | -0.66±1.23 | 0.002 | 0.012 |
| | P-value* | 0.945 | 0.059 | 0.045 | | |
| | Adjusted P-value [†] | 0.959 | 0.133 | 0.109 | | |
| Lymphocytes (x10 ³ /ul) | VLCD (n=43) | 2.26±0.66 | 1.96±0.5 | -0.30±0.40 | <0.001 | 0.001 |
| | LCD (n=39) | 2.00±0.49 | 1.84±0.49 | -0.15±0.40 | 0.022 | 0.070 |
| | P-value* | 0.051 | 0.277 | 0.100 | | |
| | Adjusted P-value [†] | 0.119 | 0.422 | 0.200 | | |

| | | | | | | |
|---|--|--|--|---|-----------------|----------------|
| Monocytes ($\times 10^3/\text{ul}$) | VLCD ($n=43$) LCD ($n=40$) P-value* Adjusted P-value [†] | 0.55 \pm 0.18 0.51 \pm 0.15 0.498 0.571 | 0.49 \pm 0.1 0.49 \pm 0.14 0.906 0.932 | -0.06 \pm 0.12 -0.29 \pm 0.10 0.148 0.273 | 0.001 0.097 | 0.001 0.200 |
| Protein status and inflammation | | | | | | |
| Total proteins (g/dL) | VLCD ($n=43$) LCD ($n=41$) P-value* Adjusted P-value [†] | 7.12 \pm 0.35 7.12 \pm 0.41 0.964 0.964 | 7.25 \pm 0.37 7.19 \pm 0.41 0.514 0.580 | +0.13 \pm 0.30 +0.05 \pm 0.34 0.304 0.426 | 0.009 0.336 | 0.037 0.439 |
| Albumin (g/dL) | VLCD ($n=43$) LCD ($n=41$) P-value* Adjusted P-value [†] | .34 \pm 0.23 4.32 \pm 0.25 0.882 0.933 | 4.46 \pm 0.24 4.38 \pm 0.26 0.135 0.256 | +0.13 \pm 0.22 +0.05 \pm 0.22 0.113 0.220 | 0.001 0.184 | 0.001 0.308 |
| Prealbumin (mg/dL) | VLCD ($n=43$) LCD ($n=40$) P-value* Adjusted P-value [†] | 23.75 \pm 5.51 23.55 \pm 4.04 0.849 0.914 | 20.74 \pm 4.85 21.56 \pm 5.27 0.466 0.544 | -3.01 \pm 3.97 -2.10 \pm 4.49 0.327 0.439 | <0.001 0.005 | 0.001 0.022 |
| CRP (mg/dL) | VLCD ($n=43$) LCD ($n=41$) P-value* Adjusted P-value [†] | 0.80 (0.44- 1.30) 0.70 (0.50- 1.40) 0.805 0.880 | 0.6 (0.4-1.1) 0.8 (0.5-1.3) 0.160 0.280 | -0.10(+0.10-(-0.60)) -0.05(0.18-(-0.33)) 0.292 0.423 | 0.010 0.359 | 0.039 0.441 |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyltransferase; CRP, C-reactive protein.

Parameters following a normal distribution are expressed as mean \pm standard deviation and median (interquartile range: 25-75). To determine differences between groups a t-student test was applied as well as a Mann Whitney test. The Wilcoxon test was used for nonparametric paired data.

*: P value for between-group differences.

[†]The Benjamin-Hockberg procedure for multiple-testing was used to calculate adjusted P-values, considering an FDR <0.05 as significant.

Table 6. Surgical complications from the intervention until 6 months

| | VLCD N=42 | LCD N=41 |
|----------------------------|---|---|
| Early complications | | |
| Major | Prolonged hospitalization (> 7 days): intra-abdominal collection. (LRYGB) | Prolonged hospitalization (> 7 days): infection of the wound by MARSA that required antibiotic treatment and hospitalization of more than seven days. (LRYGB) |
| | Surgical site infection (superficial, deep or organ space) requiring debridement or washout in the operating room or percutaneous intervention. (LRYGB) | Prolonged hospitalization (> 7 days): small gastrointestinal anastomosis leak that did not require reoperation. (LRYGB) |
| | Venous thrombotic event requiring administration of anticoagulant: bilateral pulmonary thromboembolism that required anticoagulant treatment. (LRYGB) | Prolonged hospitalization (> 7 days): prolonged stay in the intensive care unit for pyelonephritis caused by urinary infection. (SG) |
| | | Gastrointestinal hemorrhage requiring transfusion. (LRYGB) |
| | | |
| Minor | Urinary tract infection managed with antibiotics. (LRYGB) | Urinary tract infection managed with antibiotics. (LRYGB) |
| | Symptomatic cholelithiasis. (LRYGB) | |
| Late complications | | |
| Major | Gastric sleeve stenosis/obstruction requiring revision to a gastric bypass: gastric torsion. (SG) | Gastrointestinal hemorrhage requiring transfusion. (LRYGB) |
| | | Cholecystectomy. (LRYGB) |
| | | |
| Minor | No minor or late complications occurred | No minor or late complications occurred |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet

Table 7. Post operatory hospital stay.

| | VLCD N=42 | LCD N=41 | P-value Between groups |
|----------------------------------|----------------------|---------------------|-----------------------------------|
| Days of hospital stay | 2.8±1.1 | 3.0±1.7 | NS |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; NS, not significant.

Table 8. Dietary compliance and tolerance

| | VLCD N=42 | LCD N=41 | P-value Between groups |
|--|--|---|-----------------------------------|
| Compliance | | | |
| Returned formula sachets | 96.7±6.8% | 97.0±7.4% | NS |
| Adherence to the dietary intervention | High adherence: 94% (<i>≥80% of the sachets consumed</i>) Low adherence: 6% (<i><80% of the sachets consumed</i>). | | NS |
| Extra food | Very good or good adherence: 95.3% Regular 2.3% Poor: 2.3% | Very good or good adherence: 92.7% Regular 4.9% Poor: 2.4% | NS |
| Tolerance | | | |
| Dizziness | | | |
| <i>First week</i> | 39.5% | 12% | 0.008 |

| | | | |
|---|-------|-----|-------|
| Asthenia <i>First week</i> | 48.8% | 17% | <0.05 |
| <i>Second week</i> | 37.2% | 21% | <0.05 |
| Other recorded tolerance parameters | -- | -- | NS |
| Other results | | | |
| The percentage of weight lost at 6 months of surgery was 28.8±5.4% in those individuals with high adherence (≥ 80%) and 27.5±12 in those with low adherence (<80%), P= 0.666 between high and low adherence | | | |
| No differences in the rate of surgical complications were shown between those individuals with high or lower adherence to the intervention measured by the formula sachets returned P = 0.686. | | | |

Abbreviations: VLCD, very low calorie diet; LCD, low calorie diet; NS, not significant.

Adverse Events

There were no adverse events related to the intervention